Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM)

Historical Holders from Q1 2016 to Q3 2025

Symbol: ADVM on Nasdaq
Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 22,163,711
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 506,821
Holdings value: $2,295,899
Number of holders: 1

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
TCG Crossover GP II, LLC	8.9%				1,871,482		TCG Crossover GP II, LLC	31 Mar 2025

Institutional Holders of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	506,821	$2,295,899				$4.53	1
2025 Q2	506,821	$1,089,665				$2.15	1
2025 Q1	506,821	$2,214,808				$4.37	1
2024 Q4	506,821	$2,366,854				$4.67	1
2024 Q3	506,821	$3,557,883	-$13,777,212			$7.02	1
2024 Q2	2,515,161	$17,254,004	-$15,119,117			$6.86	2
2024 Q1	3,584,406	$50,683,501	-$65,439,463	$0	$0	$14.14	3
2023 Q4	64,132,473	$48,273,518	-$1,520,387	$2,033	$41,401	$0.7528	59
2023 Q3	65,292,701	$97,938,144	-$602,707	$300	$135,300	$1.5	59
2023 Q2	65,656,058	$104,390,959	+$5,754,060		$89,517	$1.59	58
2023 Q1	62,720,205	$44,991,824	+$4,081,826	$0	$54,810	$0.7174	55
2022 Q4	57,295,790	$33,199,851	-$12,964,215	$6,781	$241,765	$0.5795	57
2022 Q3	58,514,356	$55,588,188	-$1,275,581	$10,000	$333,000	$0.95	71
2022 Q2	57,970,602	$69,560,336	-$6,820,507	$13,000	$452,000	$1.2	68
2022 Q1	62,888,494	$82,380,013	-$1,371,697	$170,000	$689,000	$1.31	83
2021 Q4	65,600,223	$115,457,496	-$8,004,076	$695,000	$2,012,000	$1.76	93
2021 Q3	69,635,091	$151,153,216	-$23,142,215	$1,471,000	$2,722,000	$2.17	106
2021 Q2	78,711,144	$275,485,634	-$213,058,010	$3,694,000	$3,328,000	$3.5	112
2021 Q1	95,104,058	$937,859,079	+$7,873,874	$10,466,000	$2,874,000	$9.86	131
2020 Q4	94,361,848	$1,022,948,988	-$6,881,994	$11,380,000	$7,151,000	$10.84	152
2020 Q3	95,172,816	$980,341,669	+$112,519,116	$4,233,000	$6,638,000	$10.3	158
2020 Q2	80,871,445	$1,688,585,259	+$34,736,142	$4,732,000	$14,879,000	$20.88	140
2020 Q1	80,026,922	$782,228,273	+$235,883,947	$917,000	$1,391,000	$9.77	125
2019 Q4	56,103,335	$646,305,236	+$34,182,922	$3,524,000	$11,848,000	$11.52	114
2019 Q3	48,990,703	$267,003,291	-$13,477,648	$5,747,000	$6,518,000	$5.45	98
2019 Q2	46,363,555	$548,900,478	+$95,034,106	$448,000	$1,227,000	$11.89	93
2019 Q1	39,718,110	$208,116,336	+$8,512,594		$0	$5.24	83
2018 Q4	38,437,133	$121,095,668	-$70,697,347	$0	$54,000	$3.15	83
2018 Q3	34,548,140	$269,455,188	-$3,691,162	$123,000	$667,000	$6.05	101
2018 Q2	36,661,531	$194,311,714	+$10,169,062	$187,000	$691,000	$5.3	99
2018 Q1	34,592,324	$200,632,035	+$91,767,314	$527,000	$2,640,000	$5.8	95
2017 Q4	19,222,404	$67,283,021	+$19,583,575	$43,000	$1,477,000	$3.5	63
2017 Q3	13,572,084	$49,476,022	+$3,295,007			$3.65	56
2017 Q2	13,013,740	$32,536,015	-$1,444,466			$2.5	60
2017 Q1	13,521,554	$36,511,138	+$2,251,986			$2.7	72
2016 Q4	15,096,238	$43,780,064	-$552,911	$18,000		$2.9	80
2016 Q3	15,269,145	$62,723,851	-$931,562	$15,000		$4.11	75
2016 Q2	15,771,305	$49,835,686	+$49,081,893	$47,000		$3.16	75
2016 Q1	226,341	$1,170,000	+$1,139,000			$5.17	3